Lipella Pharmaceuticals
LIPO
LIPO was delisted on the 18th of June, 2025.
9 hedge funds and large institutions have $260K invested in Lipella Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
29% more funds holding
Funds holding: 7 → 9 (+2)
0.04% less ownership
Funds ownership: 0.8% → 0.76% (-0.04%)
31% less capital invested
Capital invested by funds: $377K → $260K (-$117K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$20.5K |
| 2 |
HF
HRT Financial
New York
|
+$9.62K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$737 |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$60 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$18.5K |
| 2 |
Two Sigma Investments
New York
|
-$2.59K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$776 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $171K | -$18.5K | -2,492 | -7% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $28.8K | – | – | – |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $23.6K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $15.1K | +$20.5K | +2,759 | New |
|
|
5
Two Sigma Investments
New York
| $8.96K | -$2.59K | -348 | -18% |
|
|
HF
6
HRT Financial
New York
| $7K | +$9.62K | +1,292 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $5.28K | +$737 | +99 | +11% |
|
|
8
Fidelity Investments
Boston,
Massachusetts
| $45 | +$60 | +8 | New |
|
9
Wells Fargo
San Francisco,
California
| $21 | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$776 | -95 | Closed |
|
LIPO Hedge Fund Activity: Q1 2024 in Review
9 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q1 2024, worth a combined $260K — down 31% from $377K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new LIPO positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $20.5K. The largest seller was Sabby Management, cutting an estimated $18.5K.
- 9 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q1 2024, up from 7 in Q4 2023.
- Funds reported $260K of Lipella Pharmaceuticals stock for Q1 2024, down 31% quarter-over-quarter.
- 3 funds opened new Lipella Pharmaceuticals positions in Q1 2024 and 1 closed out, a net change of +2 holders.
- The largest Lipella Pharmaceuticals buyer in Q1 2024 was Citadel Advisors, an estimated $20.5K added.
- The largest Lipella Pharmaceuticals seller in Q1 2024 was Sabby Management, an estimated $18.5K sold.
Based on aggregated 13F filings for Q1 2024.